Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorder (TAND) Outcomes Following Add-on Cannabidiol (CBD) Treatment: 3-Month Analysis of Open-Label Phase 3b/4 Trial EpiCom (P8-9.005)
To investigate behavioral and co-occurring outcomes after initiation of add-on CBD treatment in patients with TSC who experience seizures (NCT05864846).
Authors
- Roy E. Strowd (ORCID: https://orcid.org/0000-0001-6651-5267)
- Teresa Greco (ORCID: https://orcid.org/0000-0002-7114-8673)
- Jane Boggs
- Sarah Wilson
- Joanne Stevens (ORCID: https://orcid.org/0000-0002-0875-577X)
- Agnies M. van Eeghen (ORCID: https://orcid.org/0000-0001-8149-8645)
- Lisa Moore-Ramdin
- Douglas M. Smith (ORCID: https://orcid.org/0000-0002-5826-2121)
Institutions
- Emma Kinderziekenhuis (NL)
- Jazz Pharmaceuticals (United States) (US)
- Minnesota Epilepsy Group (US)
- Amsterdam University Medical Centers (NL)
- Wake Forest University (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212277
- Primary Topic
- Polyamine Metabolism and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00